In short: Omega-3 supplements alone are not proven to improve hair growth. The main positive study tested a mixture of omega-3 and omega-6 oils with antioxidants in women, so it cannot show which ingredient produced the changes. Current clinical evidence remains too sparse to support omega fatty acids as a standalone hair-loss treatment.

Omega-3 supplements alone are not proven to improve hair growth. The main positive human study tested omega-3 and omega-6 oils together with antioxidants, so its results cannot be assigned to omega-3 (Le Floc’h and colleagues, 2015).

A 2026 scoping review mapped the clinical and preclinical literature and concluded that current evidence does not support omega fatty acids as a standalone treatment for any type of alopecia (Abdul-Rahman and colleagues, 2026).

Does omega 3 help hair growth?

The honest answer is that human research has not isolated omega-3 well enough to show a hair-growth effect of its own. The study most often used to support the claim was a six-month randomised comparative study involving 120 women. It compared a nutritional supplement with no supplement, rather than comparing omega-3 alone with a matching placebo (Le Floc’h and colleagues, 2015; Cochrane review).

The supplement contained fish oil, which supplied omega-3, and blackcurrant seed oil, which supplied omega-6. It also contained vitamins C and E and lycopene. Any ingredient, interaction between ingredients or difference in expectations could have contributed to the results. The trial therefore supports a finding about that complete mixture, not a general claim for fish oil or an omega-3 product (Cochrane review).

A nutrient can be present in foods or be part of normal physiology without extra supplementation being proven to reverse hair loss. The 2015 trial did not compare dietary adequacy with deficiency, and the 2026 review found that many clinical studies used combined products rather than isolated omega fatty acids (Abdul-Rahman and colleagues, 2026).

What did the main human study find?

The researchers enrolled women aged 18 to 65 with mild female pattern hair loss. Eighty were assigned to the supplement and 40 to no supplement. One person in each group withdrew, leaving 79 and 39 in the respective groups for the final analysis (Cochrane review; Abdul-Rahman and colleagues, 2026).

The study used standardised photographs to assess change in hair density. It also measured the percentage of hairs in the resting phase, the distribution of thicker and finer growing hairs, a trichometer index and the participants’ own views. After six months, the published abstract reported better photographic assessments, a lower percentage of resting hairs, a greater proportion of thicker growing hairs and a better trichometer index in the supplement group than in the control group (Le Floc’h and colleagues, 2015).

There was a controlled difference in the participants’ reports of reduced hair loss: 71 of 80 women assigned to the supplement reported a decrease, compared with 27 of 40 assigned to no supplement. That result favoured the complete product (Cochrane review).

Some widely repeated percentages come only from the supplement group. The Cochrane reviewers found that comparator data were missing for participants’ self-rated hair density and satisfaction, so those percentages could not be analysed as controlled effects. A high percentage in the supplement group, viewed by itself, cannot show how much change exceeded what happened without the product (Cochrane review).

Why does the comparison group affect confidence?

The control group received no supplement. Participants therefore knew whether they were taking the product, even though experts assessing photographs were described as blinded. Knowledge of treatment can influence subjective reports, particularly when the outcome asks whether hair seems denser or shedding seems reduced (Cochrane review).

The Cochrane reviewers rated the study at high risk of bias overall. They reported unclear methods for generating and concealing the random allocation, and high risk of detection bias because participants received no substitute capsule and were among the outcome assessors. They also noted that the first author worked for the supplement manufacturer (Cochrane review).

These limits do not mean that the measured changes did not occur. They mean the study gives less certain evidence than a trial in which participants receive visually identical products and neither group knows its assignment. The absence of a matching placebo matters most for self-reported outcomes.

Can these findings establish an omega-3 effect?

The trial was not designed to separate fish oil from blackcurrant seed oil, vitamins C and E or lycopene. It had no fish-oil-only arm, no antioxidant-only arm and no factorial comparison that could estimate each ingredient’s contribution. A retail omega-3 capsule may also differ from the studied product in formulation and accompanying ingredients.

The narrow population also limits the result. The trial concerned adult women with mild female pattern hair loss and excluded several circumstances that could affect hair, including vitamin deficiency, thyroid disorders, telogen effluvium, pregnancy and the early postpartum period. Its findings should not be transferred to men, other patterns of loss or people whose hair loss has another cause (Cochrane review).

The trial lasted six months and did not establish whether changes persisted after supplementation ended (Cochrane review).

What does the current evidence map add?

The 2026 scoping review searched five research sources from their start dates to 2 February 2026. It included 21 studies: 15 preclinical studies using cells, isolated follicles or animals, and six clinical studies that included trials, an observational cohort and case reports. The authors chose a scoping method to map varied evidence rather than pool results into one treatment-effect estimate (Abdul-Rahman and colleagues, 2026).

Most included studies did not provide a direct test of omega-3 supplements for common hair loss in adults. Laboratory and animal work can investigate what a fatty acid does to cells, cellular pathways or hair in another species, but it cannot establish that swallowing an omega-3 supplement regrows human scalp hair. The clinical studies also differed in population, hair-loss type, exposure and outcome (Abdul-Rahman and colleagues, 2026).

Among the clinical literature, the review found combined supplements, a dietary association study, a small uncontrolled study, survey-based findings and isolated case reports. It specifically noted that combined products prevent researchers from attributing any observed benefit to omega fatty acids alone (Abdul-Rahman and colleagues, 2026).

This newer review is not a fresh trial and does not turn all 21 studies into 21 confirmations. Fifteen were preclinical, and several human reports addressed unusual conditions or mixtures outside the question of standalone omega-3 for ordinary adult hair loss. Its useful contribution is the evidence map and the gaps it exposes.

Risks and what can go wrong

A label can mention omega-3 while differing substantially from the mixture studied in 2015. Choosing such a product on the strength of that trial assumes ingredient equivalence and an omega-3 effect that the research did not test.

Omega-3 supplements can also cause unpleasant taste, bad breath, headache, heartburn, nausea or diarrhoea. The US National Center for Complementary and Integrative Health describes these effects as usually mild, but the hair study did not establish the safety of every product or user (NCCIH).

Relying on a supplement claim can also delay assessment of continuing hair loss. The NHS says hair loss can be inherited, temporary or associated with causes such as illness, stress, weight loss and iron deficiency. It advises seeing a GP if you are worried and getting an idea of the cause before approaching a commercial hair clinic (NHS).

Neither a response nor a lack of response to a supplement diagnoses the cause. The omega evidence also says nothing about whether a hair transplant is suitable. Those decisions require professional assessment rather than an inference from a product label or the 2015 mixed-formula study.

Questions to ask the clinic

If omega-3 comes up while you are discussing hair loss, ask:

  1. What diagnosis explains the hair loss, and who made that assessment?
  2. Does the evidence concern omega-3 alone or a product with several active ingredients?
  3. Did the comparison group receive a matching placebo, no product or another treatment?
  4. Were the participants similar in sex, age and type of hair loss to the person being assessed?
  5. Which outcomes changed: standardised photographs, hair measurements or participants’ opinions?
  6. Were results reported for both groups, and how long did follow-up last?
  7. Is the exact retail formulation supported by a trial, or does it only share one named ingredient?

Talk it through

If the cause of your hair loss has been professionally assessed and you want to discuss whether surgery belongs among your options, GetHair can arrange a free consultation with a partner clinic. The clinic assesses suitability and makes any clinical decision.

Sources